EGF-Binding Polypeptides for Wound Healing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional negative pressure wound therapy (NPWT) does not distinguish between beneficial growth factors and detrimental inflammatory cytokines, leading to inefficient wound healing as it removes wound exudate without selectively retaining and sustaining the activity of growth factors like epidermal growth factor (EGF).

Innovation Solution

Development of polypeptides with high affinity for EGF that can bind and retain EGF, promoting its sustained release to enhance fibroblast and epithelial cell proliferation and differentiation, using sequences at least 60% identical to specific peptide sequences (e.g., WFEWPYWEMNVPDVWN) to concentrate EGF at the wound site.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Loss of substance

If conventional NPWT is used to remove wound exudate, then fluid removal is achieved, but growth factors are lost along with detrimental factors

Engineering Contradiction:

Improvegrowth factor lossVSAvoidwound healing efficiency

Core Design Contradiction:

Loss of substanceVSProductivity

Solution Approach 1:

The patent extracts and removes detrimental factors (inflammatory cytokines, bacteria) from wound exudate while selectively retaining beneficial growth factors through the polypeptide binding agents. This selective extraction resolves the contradiction by preventing growth factor loss while maintaining fluid removal benefits.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Polypeptide binding agents serve as intermediary molecules that selectively bind to growth factors in the wound exudate. These intermediaries capture growth factors before they are removed by NPWT, then release them in a sustained manner, resolving the contradiction between fluid removal and growth factor preservation.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If polypeptides are used to bind and retain EGF, then EGF concentration is improved, but device complexity increases

Engineering Contradiction:

ImproveEGF concentrationVSAvoiddressing complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent changes the chemical parameters of the dressing by incorporating polypeptides with specific binding characteristics (high affinity, selective specificity) to EGF. This parameter change enables concentrated EGF retention without requiring complex mechanical or structural modifications to the dressing system.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polypeptides effectively concentrate EGF at the wound site, improving wound healing by promoting cell proliferation and differentiation, thereby enhancing tissue growth and repair.

Implementation Method 1

The polypeptides of the present disclosure have high affinity to bind EGF and can retain EGF

Methodology Applied

Scientific EffectProtein-protein binding:

Implementation Method 2

sustain its release to maintain its activity

Methodology Applied

Scientific EffectSustained release:

Data Source

PatentUS11254716B2Peptides for binding epidermal growth factor

Publication Date: 2022.02.22 SOLVENTUM INTELLECTUAL PROPERTIES CO

AI summary

A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.